Werewolf Therapeutics (NASDAQ:HOWL) Announces Earnings Results

Werewolf Therapeutics (NASDAQ:HOWL) issued its earnings results on Tuesday. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.03), Zacks reports. Werewolf Therapeutics had a negative return on equity of 58.83% and a negative net margin of 578.80%.

Werewolf Therapeutics Stock Performance

Werewolf Therapeutics stock traded up $0.01 on Thursday, reaching $1.24. 46,609 shares of the stock were exchanged, compared to its average volume of 266,016. The firm has a fifty day moving average price of $1.37 and a two-hundred day moving average price of $1.82. The stock has a market cap of $55.04 million, a PE ratio of -0.81 and a beta of 0.37. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.29. Werewolf Therapeutics has a twelve month low of $1.03 and a twelve month high of $6.89.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on HOWL. Wedbush restated an “outperform” rating and set a $8.00 price target on shares of Werewolf Therapeutics in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Werewolf Therapeutics in a research report on Wednesday. Finally, JMP Securities dropped their price target on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research report on Tuesday, January 14th.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.